We are open as normal during COVID-19 pandemic. Order online, same day shipping out.

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 528409

CAS#: 124423-84-3

Description: Panadiplon (also known as FD-10571, FG-10571, U-78875, and NNC-140571) is a gamma-aminobutyric acid receptor agonist potentially for the treatment of anxiety.

Price and Availability

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2020-07-10. Prices are subject to change without notice.

Panadiplon is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 528409
Name: Panadiplon
CAS#: 124423-84-3
Chemical Formula: C18H17N5O2
Exact Mass: 335.1382
Molecular Weight: 335.367
Elemental Analysis: C, 64.47; H, 5.11; N, 20.88; O, 9.54

Synonym: Panadiplon; FD-10571; FD 10571; FD10571; FG-10571; FG10571; FG 10571; U-78875; U78875; U 78875; NNC-140571; NNC 140571; NNC140571

IUPAC/Chemical Name: 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-isopropylimidazo[1,5-a]quinoxalin-4(5H)-one


InChi Code: InChI=1S/C18H17N5O2/c1-10(2)23-13-6-4-3-5-12(13)22-9-19-14(15(22)18(23)24)16-20-17(25-21-16)11-7-8-11/h3-6,9-11H,7-8H2,1-2H3

SMILES Code: O=C1C2=C(C3=NOC(C4CC4)=N3)N=CN2C5=C(C=CC=C5)N1C(C)C

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:

Additional Information

Panadiplon pretreatment resulted in leftward shifts in the pentobarbital dose-response function but predominantly rightward shifts of the triazolam dose-response function. During normoxia both cotreatments with panadiplon resulted in significantly higher glycogen levels than in panadiplon cultures alone. These results suggest that cellular glycogen and subsequently ATP levels are reduced during panadiplon exposure, metabolically predisposing hepatocytes to hypoxic injury.


1: Andreu I, Mayorga C, Miranda MA. Metabolomics in drug intolerance. Curr Drug Metab. 2009 Nov;10(9):947-55. Review. PubMed PMID: 20214587.

2: Platt DM, Duggan A, Spealman RD, Cook JM, Li X, Yin W, Rowlett JK. Contribution of alpha 1GABAA and alpha 5GABAA receptor subtypes to the discriminative stimulus effects of ethanol in squirrel monkeys. J Pharmacol Exp Ther. 2005 May;313(2):658-67. PubMed PMID: 15650112.

3: Dubinsky B, Vaidya AH, Rosenthal DI, Hochman C, Crooke JJ, DeLuca S, DeVine A, Cheo-Isaacs CT, Carter AR, Jordan AD, Reitz AB, Shank RP. 5-ethoxymethyl-7-fluoro-3-oxo-1,2,3,5-tetrahydrobenzo[4,5]imidazo[1,2a]pyridine-4 -N-(2-fluorophenyl)carboxamide (RWJ-51204), a new nonbenzodiazepine anxiolytic. J Pharmacol Exp Ther. 2002 Nov;303(2):777-90. PubMed PMID: 12388665.

4: Ulrich RG, Bacon JA, Brass EP, Cramer CT, Petrella DK, Sun EL. Metabolic, idiosyncratic toxicity of drugs: overview of the hepatic toxicity induced by the anxiolytic, panadiplon. Chem Biol Interact. 2001 May 16;134(3):251-70. Review. PubMed PMID: 11336974.

5: Rowlett JK, Woolverton WL. Discriminative stimulus effects of panadiplon (U-78875), a partial agonist at the benzodiazepine site, in pentobarbital-trained rhesus monkeys. Drug Alcohol Depend. 2001 Feb 1;61(3):229-36. PubMed PMID: 11164687.

6: Yu LX. An integrated model for determining causes of poor oral drug absorption. Pharm Res. 1999 Dec;16(12):1883-7. PubMed PMID: 10644078.

7: Ator NA, Griffiths RR. Drug discrimination analysis of partial agonists at the benzodiazepine site. I. Differential effects of U-78875 across training conditions in baboons and rats. J Pharmacol Exp Ther. 1999 Jun;289(3):1434-46. PubMed PMID: 10336537.

8: Ulrich RG, Bacon JA, Cramer CT, Petrella DK, Sun EL, Meglasson MD, Holmuhamedov E. Disruption of mitochondrial activities in rabbit and human hepatocytes by a quinoxalinone anxiolytic and its carboxylic acid metabolite. Toxicology. 1998 Nov 2;131(1):33-47. PubMed PMID: 9881933.

9: Bacon JA, Cramer CT, Petrella DK, Sun EL, Ulrich RG. Potentiation of hypoxic injury in cultured rabbit hepatocytes by the quinoxalinone anxiolytic, panadiplon. Toxicology. 1996 Apr 15;108(1-2):9-16. PubMed PMID: 8644122.

10: Ulrich RG, Bacon JA, Cramer CT, Peng GW, Petrella DK, Stryd RP, Sun EL. Cultured hepatocytes as investigational models for hepatic toxicity: practical applications in drug discovery and development. Toxicol Lett. 1995 Dec;82-83:107-15. Review. PubMed PMID: 8597037.

11: Ulrich RG, Bacon JA, Branstetter DG, Cramer CT, Funk GM, Hunt CE, Petrella DK, Sun EL. Induction of a hepatic toxic syndrome in the Dutch-belted rabbit by a quinoxalinone anxiolytic. Toxicology. 1995 Apr 12;98(1-3):187-98. PubMed PMID: 7740546.

12: Speed W, Parton AH, Martin IJ, Howard MR. The use of liquid chromatography/thermospray mass spectrometry with on-line ultraviolet diode array and radiochemical detection: characterization of the putative metabolites of U-78875 in female rat faeces. Biol Mass Spectrom. 1994 Jan;23(1):1-5. PubMed PMID: 7908834.

13: Tang AH, Code RA, Himes CS. Antagonism of hypothermia produced by benzodiazepine-related compounds by U-78875 in mice. Eur J Pharmacol. 1993 May 12;236(1):1-5. PubMed PMID: 8391449.

14: Vrbanac JJ, O'Leary IA, Baczynskyj L. Utility of the parent-neutral loss scan screening technique: partial characterization of urinary metabolites of U-78875 in monkey urine. Biol Mass Spectrom. 1992 Oct;21(10):517-22. PubMed PMID: 1358209.

15: Petke JD, Im HK, Im WB, Blakeman DP, Pregenzer JF, Jacobsen EJ, Hamilton BJ, Carter DB. Characterization of functional interactions of imidazoquinoxaline derivatives with benzodiazepine-gamma-aminobutyric acidA receptors. Mol Pharmacol. 1992 Aug;42(2):294-301. PubMed PMID: 1355261.

16: Winger G, Woods JH, Patrick GA, Powell LJ, Harris LS, Nader MA, Woolverton WL. Progress report from the Testing Program for Stimulant and Depressant Drugs (1991). NIDA Res Monogr. 1992;119:625-39. PubMed PMID: 1359421.

17: Tang AH, Franklin SR, Himes CS, Ho PM. Behavioral effects of U-78875, a quinoxalinone anxiolytic with potent benzodiazepine antagonist activity. J Pharmacol Exp Ther. 1991 Oct;259(1):248-54. PubMed PMID: 1681085.

18: Sethy VH, Oien TT. Role of cGMP in the mechanism of anxiolytic activity of U-78875. Pharmacol Biochem Behav. 1991 Jun;39(2):379-82. PubMed PMID: 1682947.

19: Zhong WZ. Determination of 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(1-methylethyl)imidazo[1, 5-a]quinoxalin-4(5H)-one in serum by high-performance liquid chromatography. J Chromatogr. 1991 Feb 15;563(2):427-34. PubMed PMID: 2056007.